{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"No"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"CBR is defined as the number of patients with CR, partial response (PR) or stable disease (SD) (for at least 12 weeks) divided by the number of patients in the analysis set.","groups":[{"description":"Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.\n\nRetifanlimab: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.","id":"OG000","title":"Interventional Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression or treatment discontinuation, up to 10.3 months","title":"Efficacy Determined by Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Participants"}